Susan Cheng, MD, MPH, MMSc, recalls hearing the first reports of a mysterious illness in China early last year and thinking: “This is going to be important.”
Lisa Stewart doesn’t dwell on the fact that she might be the first in the nation to undergo both mitral and tricuspid valve replacement procedures. She’s too busy counting her blessings.
Three years after the ALLSTAR clinical trial ended prematurely, the study’s data shows that treatments of cardiosphere-derived cells — the same cells used as an experimental therapy tested in COVID-19 patients — demonstrated unexpected promise in heart attack survivors. Downloadable video available.
Four of six critically ill COVID-19 (coronavirus) patients significantly improved after receiving an experimental therapeutic designed to reduce inflammation, a major cause of death from this disease, according to a case series published by Cedars-Sinai and Capricor Therapeutics. The four patients got well enough to be discharged from the hospital.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. The study appears on the New England Journal of Medicine site.